Weak Q1 masks long-term nuclear/infra tailwinds; near-term margin pressure
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Achieved 17% CAGR revenue and 22% CAGR PAT historically. Q1 miss is material—both revenue and profit below prior guidance; company defaulting to H2 recovery and long-term narrative.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
KSB delivered soft Q1 (3.6% revenue, -18.8% PAT) blamed on geopolitical crisis, supply-chain stress, and commodity inflation in fixed-price contracts. Management is defending near-term through cost control and hoping H2 recovery, but near-term visibility is weak and nuclear project execution is delayed. Long-term nuclear/data-centre tailwinds are real, but structural. Awaiting execution risk: GHAVP testing resolution, export clearance normalization, and competitor pressure on nuclear.
₹690.7 Cr
Revenue · +3.6% YoY₹57.2 Cr
Reported PAT · −18.8% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Geopolitical crisis, supply chain issues temporary drivers of H1 weakness
Revenue +3.6% YoY despite claims of growth opportunities; OPM 11.8% vs 13-14% target
Partially Supported
Strong order intake growth and order book ₹27,445 Cr in June 2026
Order intake H1 FY27 ₹15,307 Cr (excluding nuclear) at 14% CAGR; reported but actual growth rate not disclosed
Unverified
Expected much better performance in H2 with export recovery
As of call (August), exports have not yet recovered; only inquiries and projects started, results awaited
MISS
Valves margin decline temporary; will return to double-digit
H1 valves margin fell to single-digit from mid-teens historically; company concedes need for sales recovery to normalize
OVERSTATED
Earnings quality
What changed since the last call
Export headwinds & supply-chain stress materialized
DowngradeH1 exports faced geopolitical delays (war, tariffs); supply-chain issues cut production. 80-85% resolved now but full recovery delayed to H2. Inventory backlog still being diluted.
Solar business derailed; KUSUM 2.0 delayed
DowngradeSolar revenue ₹50-60Cr (H1) vs expectations; only 5-7% of order book. Prior guidance implied stronger ramp. Scheme delay pushed recovery to Q3/Q4.
Valves margin collapse—not temporary
DowngradeValves fell to single-digit margins vs mid-teens historically. Company attributes to commodity costs & export mix but hasn't passed full costs to customers; mitigation vague.
Nuclear testing delays; GHAVP stalled
DowngradeGHAVP testing hit issues at NPCIL test-bed (outside KSB's control). Testing now expected Sep 2026 onward. Revenue recognition pushed back further; execution risk remains on new tenders.
Full-year growth guidance softened
NeutralPrior calls guided 15-20% revenue growth & 13-14% EBITDA. Now aiming for 'double-digit' (10%+) and 15-17% 'average,' more hedged. No explicit cut but tone is cautious.
The Q&A
Analysts pressed hard on margin compression (valves, foundry costs), project business slowdown, nuclear execution delays, and capex intensity. Management defended with temporary factors (geopolitical, supply chain) and H2 recovery hopes, but offered few quantitative commitments. Q&A showed skepticism on near-term visibility; management held firm on long-term positioning.
Macro growth & sector outlook — Saurabh Mehta, East Lane Capital
AnsweredEnergy (nuclear, conventional, renewable) leading; infrastructure (water, wastewater, airports, metros) secondary. Thermal 50GW under construction offers growth. Localization drives incremental opportunities.
Nuclear execution & competition — Saurabh Mehta, East Lane Capital
PartialKudankulam safety package on track; GHAVP testing stalled on NPCIL test-bed issues, resuming Sep. New tender 'next few months' for ~8 reactors. KSB is approved supplier; NPCIL decides competition.
H1 subdued performance — Shubham Murade, ICICI Securities
AnsweredGeopolitical war halted export deliveries; ready pumps stuck. Supply chain issues resolved 80-85%. Data Centre growing globally; India focusing on liquid cooling, OEM orders emerging.
Nuclear pump execution cycle — Unidentified Analyst
AnsweredLocalization = parts previously imported now Made in India (mechanical seals, rotor parts, castings, Hurth gears). Design/tech from parent. Kudankulam redesigned in India due to geopolitical shifts.
Nuclear pump execution cycle & timeline — Unidentified Analyst
AnsweredStandard cycle 24-36 months; deliveries to NPCIL ~48 months from order. Primary coolant pump ordered early (with steam generator). Testing dependent on NPCIL test-bed.
Valves margin collapse — Unidentified Analyst
PartialCommodity prices, product mix, exports down, sales down. Combination of factors. Temporary; expect double-digit margin once sales recover and situation normalizes.
Solar business & KUSUM 2.0 — Unidentified Analyst
AnsweredSolar H1 ₹50-60Cr (much below expectations) due to KUSUM 2.0 delayed to Q4. Got Maharashtra tender orders; expect pickup in Q3. Only 5-7% of order book vs 10-12% target.
Order intake growth slowdown — Mohit Surana, Monarch Networth Capital
AnsweredStandard business growing but takes time (new markets: fire-fighting, marine, mining). Project market (oil & gas, petrochemical) slowed. Water/wastewater re-entering after years; product development underway. Supercritical thermal breakthrough (boiler circulation pump localized). Selective approach.
Full-year growth guidance — Mohit Surana, Monarch Networth Capital
PartialGoal is double-digit growth. Nuclear testing delay a risk but low. Average 15-17% reasonable; 20% possible but peaky and unreliable. 10-15% volume, 15% value a good base.
Gas/commodity cost pass-through — Mohit Surana, Monarch Networth Capital
AnsweredFoundries given 12-15% price increases; company passing single-digit to customers (phased). Margins under pressure 3-6 months lag. 85-90% supply stability now; cost agreements settled.
BP&CL integration & trajectory — Unidentified Analyst
PartialPSU business requires proven track record (PTR), public tendering (GeM portal). Building inroads to ONGC, Oil India. Reciprocating pump EIL approval being pursued. Medium-term target ₹40-50Cr annually. Takes time in Indian PSU context.
SupremeServ aftermarket growth — Unidentified Analyst
AnsweredDedicated Chinchwad facility; warehouse for spare parts giving steady monthly revenue. Boiler circulation pump refurbishment orders started (new). Descaling pump localization orders (Japanese suppliers being replaced). Growing 15% p.a. Target 25-30% revenue share (excluding agri, lower is ok vs global 35%).
Export performance & order book — Unidentified Analyst
PartialCurrent order book ~15% of sales (target 20%). Potential high but geopolitical disruptions (US tariffs, Middle East war) unpredictable. US boiler feed pumps for gas power plants, Middle East API leader, desalination market potential.
Receivables days trend — Unidentified Analyst
AnsweredSolar business caused spike (state government payment lags, fund availability). Expect good momentum in H2 but won't improve dramatically (average metric). Documentation/fund availability dependent.
JJM water scheme & BP&CL track — Unidentified Analyst
PartialJJM: positivity but still struggling on past projects; not yet visible. BP&CL: on track; PSU business takes time; building step-by-step. Targeting ₹40-50Cr annually.
Engineered pumps & project decline — Unidentified Analyst
PartialFirst half slow on project pumps; many projects waiting to finalize (temporary). Inventory mainly export orders awaiting clearance, FGD business closure, solar slowdown. Not nuclear. Will be diluted.
HANA implementation risk — Unidentified Analyst
PartialS/4HANA mandatory; will improve internal efficiency, remove workarounds. Lift-and-shift phase then innovation. OpEx impact next year (shared with group). Not quantified; board to approve.
Guidance
Double-digit growth for full year; 15-17% average reasonable; 20% possible but peaky
MediumAiming for but hedged due to nuclear delays, export recovery uncertainty, and project finalization lag. H2 expected much better. Risks: GHAVP testing resolution, new tender timing.
EBITDA margins target 13-14%; maintained
LowH1 OPM 11.8% vs target. Company cites temporary factors (commodity inflation, fixed contracts). Expects mitigation through higher sales volume and cost reduction. Timeline not specified.
Annual CapEx ₹80-100-120Cr (sustenance + growth); nuclear capacity +20% at Shirwal
HighMix of machine replacement, nuclear/product development, office upgrades for employee engagement. Annual run-rate committed.
Risks the call surfaced
Nuclear execution
HighGHAVP primary coolant pump testing stalled due to NPCIL test-bed issues. Testing delayed to September. Revenue recognition pushed back. New tender timing uncertain.
Margin compression
HighFixed-price project contracts under pressure from foundry cost inflation (12-15% hikes). Company only passing single-digit increases to customers in standard business. Gross margins compressed; OpEx also hit.
Export disruption
HighH1 exports suffered from geopolitical crisis (war). Ready-for-delivery pumps stuck. Supply-chain issues (85-90% resolved) still impacting delivery. Inventory backlog ₹15-20Cr being diluted. Export order book recovery timing uncertain.
Valves margin collapse
MediumValves division margin fell to single-digit (from mid-teens historically) due to commodity prices, product mix, and export volume decline. Company attributes to temporary factors but timing for recovery vague.
Solar business slowdown
MediumKUSUM 2.0 scheme delayed to Q4; H1 solar revenue ₹50-60Cr (5-7% of order book) vs expectations of 10-12% target share. Product development time required for new segments. Receivables days impacted by state government payment lags.
Nuclear competition
MediumAnalyst question on Kirloskar Brothers and Flowserve entering primary coolant pump space. NPCIL approval not exclusive; new tenders may introduce competition. KSB has 47 years experience and learning curve advantage but not guaranteed monopoly.
Management
Score 6/10. Transparent on headwinds (geopolitical, supply-chain, commodity inflation) but overly reliant on 'temporary' narrative. Specific numbers on cost recovery and margin timelines sparse. Open Q&A but deflects on quantitative guidance. Historical 17% CAGR revenue, 22% CAGR PAT but Q1 missed guidance badly (3.6% revenue, -18.8% PAT). Nuclear project delays show execution dependency on external partners. Supply-chain stabilization claims partially validated (80-85% done).
1 · August 2026 (now)
GHAVP nuclear pump testing expected to resume after test-bed issue resolution
2 · September 2026
GHAVP 500-hour pump test cycle begins; 2-3 month duration to validation & dispatch
3 · Next few months
New nuclear tender for 8 reactors (Mahi Banswara, Ashvini JV) expected; KSB is approved supplier
Awaiting execution risk: GHAVP testing resolution, export clearance normalization, and competitor pressure on nuclear.
Informational and educational content only. Not investment advice.